Recruiting

4

7188

RoW

Remimazolam, Propofol

Nanfang Hospital of Southern Medical University

Anesthesia, Surgery-Complications

12/24

12/27

Recruiting

3

1000

Europe, Canada, US, RoW

IVA337, Lanifibranor, Placebo

Inventiva Pharma

NASH - Nonalcoholic Steatohepatitis

09/25

09/26

Recruiting

N/A

1250

RoW

EEG(Electroencephalogram) change

Air Force Military Medical University, China

Aging, Postoperative Cognitive Dysfunction, EEG With Periodic Abnormalities

03/23

04/23

Recruiting

N/A

3600

RoW

no intervention

Shengjing Hospital, Beijing Institutes of Life Science, Chinese Academy of Sciences

Infertility, Microbiome

09/23

09/24

Recruiting

N/A

1146

RoW

Using DNA methylome to select embryos, Using morphologic score to select embryos

Shandong University, RenJi Hospital, Reproductive & Genetic Hospital of CITIC-Xiangya, Nanjing Maternity and Child Health Care Hospital, ShangHai Ji Ai Genetics & IVF Institute, Suzhou Municipal Hospital, The First Hospital of Jilin University, Sir Run Run Shaw Hospital, The Affiliated Hospital Of Guizhou Medical University, The Second Hospital of Hebei Medical University, Third Affiliated Hospital of Zhengzhou University, Ruijin Hospital, International Peace Maternity and Child Health Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Hainan Medical University, The First Affiliated Hospital of Anhui Medical University, Fujian Maternity and Child Health Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital with Nanjing Medical University, 900 th Hospital of Joint Logistics Support Force, Guangzhou Womenand Children's Medical Center, Changhai Hospital, Shenzhen Maternity & Child Healthcare Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Jining Medical University, Siriraj hospital, Mahidol university, Thailand

Reproductive Techniques, Assisted, DNA Methylation

06/24

05/25

Recruiting

N/A

80

RoW

Online art game intervention group

Fujian Medical University

Mild Cognitive Impairment, Subthreshold Depression

12/24

12/24

Recruiting

N/A

5000

RoW

pepsinogen

Second Affiliated Hospital, School of Medicine, Zhejiang University, Jilin City People's Hospital, No. 924 Hospital of the People's Liberation Army of China, Kunshan Hospital of Traditional Chinese Medicine, Chinese PLA General Hospital, Sichuan Provincial People's Hospital, Affiliated Hospital of Southwest Medical University, Zhongshan Hospital Xiamen University, Jingzhou Hospital of Traditional Chinese Medicine, Changhai Hospital

Gastric Cancer, Precancerous Lesion, Helicobacter Pylori Infection

12/22

12/23

Not yet recruiting

3

933

NA

Chemoradiation, FOLFOXIRI Protocol, Folfox Protocol

Sixth Affiliated Hospital, Sun Yat-sen University

Rectal Cancer, Chemotherapy Effect

07/24

07/29

Recruiting

N/A

1200

RoW

Stool DNA test, Blood mRNA test, FIT Assay

Sixth Affiliated Hospital, Sun Yat-sen University, Changhai Hospital, Tianjin Nankai Hospital

Colorectal Cancer, Colorectal Adenomatous Polyp

06/23

06/23

Recruiting

1

400

Europe, US, RoW

KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib

Pierre Fabre Medicament

Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma

12/24

12/25

Recruiting

1

750

Europe, Japan, US, RoW

LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab

Eli Lilly and Company

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor

01/30

01/30

Completed

N/A

46

US

MicroOrganoSphere (MOS) drug screen

Xilis, Inc.

Colorectal Neoplasms

11/23

03/24

Recruiting

3

351

RoW

RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan

RemeGen Co., Ltd.

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma

12/24

06/25

Active, not recruiting

3

528

RoW

mFOLFOXIRI plus Bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, mFOLFOX6 Plus Bevacizumab

Yanhong Deng

Colorectal Cancer

01/24

06/26

Recruiting

3

500

RoW

Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, Restaging, Concomitant Chemoradiotherapy, Surgery, Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging), Induction chemotherpay with FOLFOX

Yanhong Deng

Rectal Cancer

02/26

02/26

Not yet recruiting

3

340

NA

mFOLFOXIRI, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, mFOLFOX6

Yanhong Deng

Colorectal Cancer

07/25

07/27

Recruiting

3

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

Not yet recruiting

2

130

RoW

MAX-40279-01, regorafenib

Maxinovel Pty., Ltd.

Metastatic Colorectal Cancer

05/22

10/23

Recruiting

2

100

RoW

Toripalimab, Tuoyi

Shanghai Junshi Bioscience Co., Ltd.

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

12/22

03/23

Recruiting

2

150

RoW

Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months, Toripalimab, Celecoxib, Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months, Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months, Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months

Sun Yat-sen University

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy

04/27

04/30

Terminated

2

6

RoW

Infigratinib, BGJ398, BBP-831

LianBio LLC

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

05/24

05/24

Active, not recruiting

2

103

RoW

Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan

Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany

BRAF V600E, Metastatic Colorectal Cancer

12/23

01/25

Recruiting

2

44

RoW

Rego+Tori+Cele, Bayer AG, Innovent Biologics

Sun Yat-sen University

Colorectal Cancer, Liver Metastases, MSS

09/25

12/25

Recruiting

2

36

RoW

Surufatinib, SULANDA, Sintilimab, IBI308, Capecitabine, Capecitabine tablets

Sun Yat-sen University

Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic

11/24

11/25

Recruiting

2

143

RoW

mFOLFOXIRI + Cadonilimab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Cadonilimab (AK104), mFOLFOX6, mFOLFOXIRI

Sun Yat-sen University

Colorectal Cancer

12/24

12/25

Recruiting

2

276

RoW

LM302+Toripalimab, LM302+JS001

LaNova Medicines Zhejiang Co., Ltd.

Gastric Cancer, Pancreatic Cancer

07/25

01/26

Recruiting

1/2

320

RoW

TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab

Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb

Advanced Cancer

02/25

05/25

Not yet recruiting

1/2

74

RoW

Liposomal irinotecan, Bevacizumab, avastin

Sun Yat-sen University

Colorectal Cancer

06/25

07/26

Recruiting

1/2

152

US, RoW

EMB-01, FIT-013a

Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc

Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor

12/25

12/25

Recruiting

1

259

RoW

JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan;

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Advanced Solid Tumor

12/21

06/22

Recruiting

1

60

RoW

SG1906

Hangzhou Sumgen Biotech Co., Ltd.

Locally Advanced Unresectable or Metastatic Solid Tumors

02/25

08/25

Recruiting

N/A

392

RoW

Radical total mesorectal excision, Salavge Adjuvant Chemoradiotherapy

Sun Yat-sen University

Chemotherapy Effect, Rectal Cancer

12/28

12/28

Recruiting

4

200

RoW

Oral bifidobacterium triple live powder, Conventional treatment, Sunbathing, Sunbathing and the Oral bifidobacterium triple live powder

Zhuhai Center for Maternal and Child Health Care, Children's Hospital of Chongqing Medical University

Hyperbilirubinemia, Neonatal

06/24

06/24

Active, not recruiting

3

250

Europe, Canada, Japan, US, RoW

LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

Recruiting

3

244

RoW

Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab

Beijing InnoCare Pharma Tech Co., Ltd.

DLBCL

09/28

12/29

Active, not recruiting

3

150

RoW

SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)

Antengene Corporation

Relapsed or Refractory Multiple Myeloma

Recruiting

3

225

Europe, Canada, Japan, US, RoW

Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)

F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi

Invasive Aspergillosis

09/25

11/26

Recruiting

3

170

RoW

IMM01, Timdarpacept, Azacitidine, Placebo

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Chronic Myelomonocytic Leukemia

10/26

10/29

Recruiting

3

182

RoW

Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Graft-versus-host Disease

10/29

12/30

Recruiting

3

356

RoW

Orelabrutinib and R-CHOP, R-CHOP

Beijing InnoCare Pharma Tech Co., Ltd.

Treatment-naїve Mantle Cell Lymphoma

12/24

12/27

3

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

Recruiting

3

552

RoW

Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA)

TJ Biopharma Co., Ltd.

Myelodysplastic Syndromes(MDS)

03/27

03/27

Active, not recruiting

3

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

Recruiting

2/3

142

RoW

avatrombopag, Doptelet, Placebo

Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University

Thrombocytopenia, Stem Cell Transplant Complications

10/24

10/25

Recruiting

2/3

200

RoW

repeated transcranial magnetic stimulation (continuous theta-burst stimulation), sham repeated transcranial magnetic stimulation

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Mental Health Center, Zhengzhou Children's Hospital, China, Qilu Hospital of Shandong University

Autism Spectrum Disorder

09/25

12/25

Recruiting

2

150

RoW

AZD4205

Dizal Pharmaceuticals

Peripheral T Cell Lymphoma

05/25

12/26

Recruiting

2

75

RoW

APG2575

Ascentage Pharma Group Inc.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

09/24

12/24

Recruiting

2

100

RoW

pCAR-19B cells

Chongqing Precision Biotech Co., Ltd

Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia

12/24

07/25

Recruiting

2

185

RoW

HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor

Hutchison Medipharma Limited

Marginal Zone Lymphoma, Follicular Lymphoma

04/24

12/24

Recruiting

2

60

RoW

HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2

Hutchmed

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

05/26

11/26